SCHEMBL3012854

SCHEMBL3012854

COc1ccc(OC)c(Cc2csc(N3CCC(S(=O)(=O)c4cccc(F)c4)CC3)n2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.41
MAPT P10636 4/20 0.41
RECQL P46063 2/20 0.41
USP2 O75604 1/20 0.41
HSD17B10 Q99714 1/20 0.41
LMNA P02545 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
GPR6 P46095 3/20 0.38
KCNQ1 P51787 1/20 0.38
TP53 P04637 1/20 0.37
AR P10275 1/20 0.37
POLB P06746 1/20 0.37
ADRB2 P07550 1/20 0.37
TSHR P16473 1/20 0.37
RAB9A P51151 1/20 0.36
MEN1 O00255 1/20 0.36
GFER P55789 1/20 0.36
KMT2A Q03164 1/20 0.36
HTR2A P28223 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017443 0.93 MAPT (0.41) THRBMAPTRECQLUSP2HSD17B10
SCHEMBL3004393 0.91 MEN1 (0.41) MAPTRECQLUSP2HSD17B10LMNA
SCHEMBL3021620 0.91 MAPT (0.45) MAPTRECQLUSP2HSD17B10LMNA
SCHEMBL3019030 0.90 KDM1A (0.39) MAPTRECQLUSP2HSD17B10LMNA
SCHEMBL3016957 0.90 TP53 (0.37) MAPTRECQLUSP2HSD17B10LMNA
SCHEMBL2999753 0.90 MAPT (0.45) MAPTRECQLUSP2HSD17B10LMNA
SCHEMBL3017438 0.89 KDM4E (0.43) MAPTRECQLUSP2HSD17B10LMNA
SCHEMBL3011665 0.88 MAPT (0.39) THRBMAPTRECQLUSP2HSD17B10
SCHEMBL3018482 0.88 SMN1; SMN2 (0.43) THRBMAPTRECQLUSP2HSD17B10
SCHEMBL3014427 0.87 MAPT (0.45) THRBMAPTRECQLUSP2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA THRB 2628/4885MAPT 18/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.